Skip to Content
Merck
  • The interaction of the von Hippel-Lindau tumor suppressor and heterochromatin protein 1.

The interaction of the von Hippel-Lindau tumor suppressor and heterochromatin protein 1.

Archives of biochemistry and biophysics (2012-01-12)
Yanlai Lai, Meihua Song, Kevin Hakala, Susan T Weintraub, Yuzuru Shiio
ABSTRACT

Inactivation of the von Hippel-Lindau (VHL) tumor suppressor is associated with renal carcinoma, hemangioblastoma and pheochromocytoma. The VHL protein is a component of a ubiquitin ligase complex that ubiquitinates and degrades hypoxia inducible factor-α (HIF-α). Degradation of HIF-α by VHL is proposed to suppress tumorigenesis and tumor angiogenesis. Several lines of evidence also suggest important roles for HIF-independent VHL functions in tumor suppression and other biological processes. Using GST-VHL pull-down experiment and mass spectrometry, we detected an interaction between VHL and heterochromatin protein 1 (HP1). We identified a conserved HP1-binding motif (PXVXL) in the β domain of VHL, which is disrupted in a renal carcinoma-associated P81S mutant. We show that the VHL P81S mutant displays reduced binding to HP1, yet retains the ability to interact with elongin B, elongin C, and cullin 2 and is fully capable of degrading HIF-α. We also demonstrate that HP1 increases the chromatin association of VHL. These results suggest a role for the VHL-HP1 interaction in VHL chromatin targeting.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-ubiquityl-Histone H2A Antibody, clone E6C5, clone E6C5, Upstate®, from mouse
SKU
Pack Size
Availability
Price
Quantity